Katz Biotech AG Overview
Note on headcount. A Patsnap estimate of "<10" employees is implausible against observable operations. Those operations include greenhouse rearing of 15 beneficial species at Baruth, a separate Berlin research centre with seven named research staff, a B2B and B2C e-commerce operation, and dedicated field advisers. In addition, North Data indicates the company has filed a profit and loss statement since FY2019, having previously filed a balance sheet only. Under German disclosure rules (§§ 267, 325–327 HGB), this pattern is consistent with the company moving out of the "small company" size class. That class is defined by thresholds on employees, revenue and balance-sheet total. This is an analytical inference, not a disclosed figure, and actual headcount remains not publicly disclosed.
Katz Biotech AG is an owner-managed German specialist in biological crop protection. Its core business is the mass rearing, sale and agronomic support of "Nützlinge", the beneficial insects, mites and nematodes used to control plant pests in greenhouses, horticulture, interior landscaping, private gardens and, more recently, livestock barns. The company rears about 15 beneficial species in-house at Baruth/Mark south of Berlin and resells more than 40 further products to offer a full range. It sells to commercial growers across Germany and the rest of Europe and to hobby gardeners through its own web shop. It is differentiated from far larger Benelux peers such as Koppert and Biobest by an unusually research-intensive model for its size. That model includes a Berlin insect-technology centre, a continuous stream of publicly funded collaborative research projects, and proprietary micro-encapsulation IP that underpins products such as nemaplus® Depot. It is a niche, family-controlled player in a consolidating global biocontrol industry.
What the company does
Katz Biotech AG produces and distributes living biological control agents ("macrobials"): predatory mites, parasitoid wasps, predatory insects and entomopathogenic nematodes. Growers release these to suppress pest populations instead of, or alongside, chemical pesticides. The company states that it rears 15 different beneficial species itself and buys in more than 40 further beneficial products to cover the full current range, and that it continually works to add new species and new biological methods (Über uns, katzbiotech.de, accessed Oct 2026).
Around this core, the business has four adjacent activity streams:
-
Advisory services. On-site and remote consulting to integrate beneficials into growers' pest-management programmes. The company explicitly positions tailored advice as part of the offer, and in livestock farming it advertises free, non-binding consulting (Über uns; Herdenschutz page).
-
Contract research and entomology services. From the Berlin ITC: rearing-process optimisation, synthetic diet development, new rearing methods, strain selection and isolation, sustainable shipping packaging, and supply of pest and beneficial insects for ecotoxicology studies (F&E page).
-
Encapsulation technology services. The company offers to convert customers' liquid or oily diets, active ingredients, bacteria or entomopathogenic nematodes (EPNs) into spreadable capsule formats. It specialises in liquid-core and matrix capsules (F&E page).
-
Training and knowledge products. The recurring "Pflanzenschutzstunde" webinar series, a beneficials brochure, posters and a YouTube channel (Aktuelles page).
Business and revenue model
| Revenue stream | Nature | Disclosure status |
|---|---|---|
| Sale of self-reared beneficials (approx. 15 species) | Product, recurring and seasonal; living perishable goods shipped to order | Revenue n/d |
| Resale of bought-in beneficial products (40+) | Product (distribution / trading margin) | Revenue n/d |
| Proprietary formulated products (e.g. nemaplus® Depot capsules) | Product, IP-protected | Revenue n/d |
| Livestock fly control (e.g. VENDEX) | Product plus advisory | Revenue n/d |
| Contract research and entomology services | Service | Revenue n/d |
| Encapsulation development services | Service / potential licensing | Revenue n/d |
| Public research grants | Grant income (other operating income) | Individual awards disclosed in federal funding catalogue (see Section 13) |
The mix between product, service and licensing revenue is not publicly disclosed. Based on the company's description, the business is predominantly a product business: living organisms sold per unit or per pack, priced per release quantity. Services and grants are a secondary, R&D-funding stream.
Value chain position
Katz Biotech is vertically integrated across:
Upstream: proprietary rearing (in-house colonies, host and diet systems, strain selection);
Midstream: packaging and cold-chain logistics of perishable living organisms;
Downstream: direct sale and agronomic advice to end users.
It also acts as a distributor for third-party beneficials to complete its range. This combination of producer, distributor and advisor is typical of mid-sized European insectaries.
Customer types and end-markets
| Customer type | Channel | Evidence |
|---|---|---|
| Commercial horticulture (greenhouse vegetables, ornamentals, nurseries) | B2B shop (b2b.katzbiotech.de), advisers, annual commercial assortment list | Home page; "Sortimentsliste 2026 für Gewerbekunden" |
| Retail garden centres / end-sale nurseries | B2B, advisory webinars on beneficial use in retail | Webinar "Nützlingseinsatz im Endverkauf" (Aktuelles) |
| Private gardeners / households ("Haus und Garten") | B2C web shop | Home page |
| Organic and conventional fruit and vegetable growers (open field) | Advisory and research projects | KOBE, BiWaReg, ParaDrosu projects (F&E) |
| Livestock farms (dairy, cattle barns) | Dedicated Herdenschutz advisory | Herdenschutz page |
| Building-greening / interior landscaping | Knowledge partner (HU Berlin webinar) | Aktuelles page |
| Agrochemical / biologicals companies, research institutes | Ecotox insects, encapsulation, contract R&D | F&E page |
Geographically, the company states that its advice and deliveries cover Germany and the rest of Europe (Home page).
Company's own description vs independent characterisation
Company description (paraphrased). Since 1992 the company has specialised in producing and applying beneficial organisms for biological plant protection, serving horticultural businesses and private gardeners in Germany and across Europe. Its stated mission is to advance the role of beneficial insects in agriculture as an alternative to chemical pesticides (Home and Über uns pages). No annual report narrative is publicly accessible.
Independent characterisation. Katz Biotech is best characterised as a research-led German regional insectary with a disproportionately strong grant-funded innovation engine relative to its commercial scale. Its commercial core is a seasonal, logistics-intensive macrobial business exposed to greenhouse horticulture cycles. Its strategic optionality lies in:
-
encapsulation IP (liquid-core capsules for nematodes and attract-and-kill);
-
novel parasitoids for invasive pests (spotted-wing drosophila, invasive stink bugs);
-
insect-biomass and feed patents linked to a Hermetia (black soldier fly) holding;
-
automation of predatory-mite rearing.
It is a price-taker relative to the global leaders and relies on niche specialisation, proximity to German growers and advisory intimacy.
Strategy
Stated strategy (themes paraphrased from company communications)
No annual report narrative or investor-day material is publicly available. The website sets out the following strategic themes (paraphrased):
-
Advance beneficial insects as the alternative to chemical pesticides. Clean food production, biodiversity protection, and the view that biological pest control is the future of agriculture (Home; Über uns).
-
Customer intimacy through close cooperation with farmers, delivering tailored solutions (Über uns).
-
Continuous expansion of the self-reared species range and development of new biological methods (Über uns).
-
Innovation in rearing efficiency and application technology: automation, diets, lighting, encapsulation and drones (F&E).
-
Sustainability in operations: packaging from renewable raw materials (F&E).
Strategic initiatives (last 24 months, Oct 2024 to Oct 2026)
| Initiative | Type | Start | Target / goal | Status | Source |
|---|---|---|---|---|---|
| Livestock fly control ("Herdenschutz") incl. VENDEX | New business line | c. 2025–2026 | Enter biological fly control in animal husbandry | Launched; advisory active | Herdenschutz page |
| NemaKaps | Product development (encapsulated EPNs vs vegetable flies) | Oct 2024 | Field-ready capsule application | Project end Mar 2026; interim results presented 2026 | F&E; North Data |
| DHYNAMite | Precision biocontrol (drones plus hyperspectral detection) | Aug 2025 | Detect spider-mite hotspots; targeted predator release | Ongoing | North Data |
| AutoMiTec | Production automation | Jan 2026 | Solid-state bioreactor for automated predatory-mite propagation | Ongoing | North Data |
| Resilience in organic vegetable growing | Practice research | Dec 2025 | Strategies and innovations for organic vegetables | Ongoing | North Data |
| BiWaReg | Novel biocontrol agent | Apr 2022 | Trissolcus cultratus vs red-legged shield bug | Ongoing to Sep 2027 | F&E |
| Digital channel relaunch (B2C/B2B shops) | Commercial infrastructure | c. Sep 2024 | Separate commercial and consumer e-commerce | Live | Website |
| Webinar programme ("Pflanzenschutzstunde") | Customer education / marketing | Ongoing | Customer engagement, thought leadership | Next session 23 Nov 2026 | Aktuelles |
| Encapsulation-as-a-service | Technology commercialisation | Ongoing | Third-party capsule development | Offered | F&E |
ESG commitments and cost programmes
ESG: no formal targets disclosed. The business model is inherently aligned with pesticide reduction.
Cost programmes: none disclosed. The AutoMiTec automation project implicitly targets lower rearing labour cost.
Medium-term financial targets and guidance
None published. The company does not issue guidance.
Products & Services
Important limitation. The company publishes a full commercial assortment list ("Sortimentsliste 2026 für Gewerbekunden") and a 2025 beneficials brochure as PDF downloads. The entries below are restricted to products and organisms verifiably named in public company or third-party material. Species not confirmed in company material are deliberately excluded rather than inferred from industry norms.
Crop protection – Commercial and Home & Garden
| Product / offering | Description and capability | Target customer | Launch / version | Pricing | Source |
|---|---|---|---|---|---|
| Self-reared beneficials range (about 15 species) | Insects and mites reared at Baruth for release against greenhouse and garden pests | Growers, gardeners | Ongoing since 1992 | Per pack or release unit; prices in web shop (n/d in summary) | Über uns |
| Bought-in beneficial products (40+) | Third-party beneficials to complete the range | Growers, gardeners | Ongoing | — | Über uns |
| Phytoseiulus persimilis (predatory mite) | Specialist predator of spider mites; presented by Dr. Katz as part of the range in 2007 | Greenhouse vegetables, ornamentals | Long-standing | — | DPG protocol 2007 |
| nemaplus® Depot | Steinernema feltiae nematodes embedded in liquid-core capsules. Capsules are worked into potting soil and release nematodes as they dissolve or are chewed by larvae. The nematodes then infect fungus-gnat larvae via a symbiotic bacterium. Described as preventive and safe for people and pets. | Houseplant owners, growers, retail | Co-developed with e-nema GmbH; company describes it as worldwide unique | — | F&E page; nemaplusdepot.com; BioProtection Portal |
| Encapsulated EPNs against vegetable flies (NemaKaps) | Capsule-based nematode delivery against vegetable flies (e.g. cabbage and onion fly types); interim results presented in 2026 webinar | Field vegetable growers | Development (project to Mar 2026) | Not commercial yet | F&E; Aktuelles |
| Pupal parasitoids vs. Drosophila suzukii (e.g. Trichopria drosophilae) | Practical release of pupal parasitoids against spotted-wing drosophila (ParaDrosu) | Berry, cherry and fruit growers | Research 2021–2025; commercial status n/d | — | F&E |
| Trissolcus cultratus (egg parasitoid) | Biological control of red-legged shield bug in organic orchards (BiWaReg) | Organic fruit growers | Research to 2027 | Not commercial yet | F&E |
| Attract-and-kill capsule system ("A&K principle") | Capsules with an attractant in the outer shell. Bugs pierce the capsule and ingest the control agent from the aqueous core. Claimed benefits: no crop contact with the plant-protection product, no pre-harvest interval, lower active-ingredient use, high selectivity, suitability for UV-unstable biologicals, machine application. | Fruit and vegetable growers; agrochemical partners | Development / technology platform | — | F&E page |
Livestock / Herd protection
| Product / offering | Description | Target customer | Launch | Pricing | Source |
|---|---|---|---|---|---|
| VENDEX | New product against stable flies, specifically house fly (Musca domestica) and stable fly (Stomoxys calcitrans). Positioned to lower disease-transmission risk, reduce chemical reliance and be safe for humans and animals. The organism or mode of action is not specified on the public page. | Dairy and livestock farms | c. 2026 ("Neu in unserem Sortiment") | — | Herdenschutz page |
| Beneficials concepts for animal housing | Farm-specific biological pest-control strategies with free advisory, led by an agricultural engineer with 25+ years of dairy experience | Farms, agricultural cooperatives | c. 2025 | Advisory free of charge | Herdenschutz page |
R&D, Technology & Services (ITC Berlin)
| Offering | Description | Target customer | Source |
|---|---|---|---|
| Rearing process optimisation | Efficiency improvement in mass rearing of beneficials | Insectaries, partners | F&E |
| Synthetic diets for beneficials | Development of new artificial feeding diets | Insectaries | F&E |
| Novel rearing methods | New insect rearing procedures; species-specific lighting (InLight); solid-state bioreactor for predatory mites (AutoMiTec) | Internal; partners | F&E; North Data |
| Strain selection and isolation | Classical breeding for high-quality beneficial strains | Internal QA | F&E |
| Sustainable shipping packaging | Packaging from renewable raw materials for living organisms | Internal; customers | F&E |
| Screening of new beneficial species | Evaluation of little-studied natural enemies | Internal; research | F&E |
| Ecotox test organisms | Supply of pest and beneficial insects for ecotoxicological studies | Agrochemical companies, CROs, regulators | F&E; statutory object |
| Micro-encapsulation services | Liquid-core and matrix capsules; aqueous or oily cores, emulsions and suspensions; optimisation of additives and process parameters | Biologicals companies, diet developers | F&E |
| Chemical entomology | Dedicated service area (details on sub-page) | Research partners | F&E (C-E link) |
Knowledge products (non-revenue / marketing)
| Item | Description | Source |
|---|---|---|
| "Pflanzenschutzstunde" webinar series | Webinars with in-house and external experts (e.g. HU Berlin); next session 23 Nov 2026 | Aktuelles |
| Beneficials brochure (2025 edition) | Guide to common pests and their natural enemies with application tips | Aktuelles |
| Commercial assortment list 2026 | Full B2B price and product list (PDF) | Aktuelles |
| Posters and YouTube channel | Educational content | Aktuelles |
Financial Narrative
Disclosure context
Katz Biotech AG files HGB single-entity annual accounts with the German company register. North Data indexes balance sheets for FY2005–FY2024 and profit and loss statements for FY2019–FY2024. As a result, every financial line item below is not publicly disclosed in the accessible sources. No estimates are provided.
Primary-source route for users: the FY2020–FY2024 accounts can be retrieved from the German Unternehmensregister (unternehmensregister.de) under Katz Biotech AG, Amtsgericht Potsdam HRB 16819 P. The accessible publication dates are listed in 6.6.
Blank cells below mean not publicly disclosed.
Income statement
Revenue CAGR FY2020–FY2024: not calculable (n/d).
EPS is not a meaningful metric for an unlisted AG with a closely held share register. The share count is not publicly disclosed; share capital was EUR 100,000 as of the 2007 publication.
Balance sheet
The subscribed capital row assumes no change since the EUR 100,000 capital publication of 20 March 2007. No later capital-change publication appears in the accessible register index.
Cash flow
Cash flow statements are not required for non-capital-market HGB single-entity accounts. They are therefore likely not prepared for publication at all, not merely inaccessible.
Commentary on trends, inflections and drivers
In the absence of numbers, the analysis relies on qualitative evidence.
(i) Size inflection around FY2019. The switch from balance-sheet-only to balance sheet plus P&L publication from FY2019 is the single most informative public signal about scale. Under German law, this disclosure change typically follows a company exceeding two of the three small-company thresholds for two consecutive years. It points to growth through the late 2010s in headcount, revenue or balance-sheet total.
(ii) Filing cadence. The FY2024 accounts were published about 13 months after year end (February 2026). Earlier years were also published about 12 months after year end. This is consistent with statutory deadlines and does not signal distress, but the cadence has drifted later.
(iii) Revenue drivers. Revenue drivers are likely to include:
-
German greenhouse vegetable and ornamental acreage and their adoption of integrated pest management (IPM);
-
the spread of invasive pests creating new demand, for example Drosophila suzukii, Halyomorpha halys and Nezara viridula;
-
the regulatory withdrawal of chemical actives in the EU;
-
weather-driven seasonal pest pressure.
(iv) Grant income as a stabiliser. Federal grants of EUR 0.18–0.40 million per year in award terms are material relative to a company of this type. They likely represent a meaningful share of R&D funding.
(v) Cost pressures. Energy costs for heated greenhouse rearing, labour costs and logistics for living goods were material headwinds for European insectaries in 2022–2023. The company's specific exposure is not publicly disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line (analytical) | Contents | Products / services |
|---|---|---|
A. Crop protection – Commercial (B2B) | Beneficials for greenhouse and field horticulture, nurseries, retail growers | 15 self-reared species, 40+ bought-in products, advisory |
B. Home & Garden (B2C) | Beneficials for private gardens, houseplants and interiors | Web shop, nemaplus® Depot (fungus gnats) |
C. Livestock / Herd protection | Biological fly control in animal housing | VENDEX, advisory concepts |
D. R&D, Contract research & Technology services | ITC Berlin: entomology services, ecotox organisms, encapsulation, publicly funded projects | Contract R&D, capsule development, grants |
Group Entities
| Entity | Relationship | Evidence | Status |
|---|---|---|---|
Katz Biotech AG | Operating parent | Register HRB 16819 P | Active |
Hermetia GbR | Holding disclosed in FY2009 accounts | North Data | Current status n/d |
PK Nützlingszuchten und Hermetia GbR | Holding disclosed in FY2012 and FY2013 accounts | North Data | Current status n/d |
Further holdings | 4 holdings (FY2014), 5 holdings (FY2015) per accounts | North Data | Names and stakes n/d |
Key Financials
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Subscribed capital (EUR Mn) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Contents Published by Fiscal Year
| Fiscal year | Contents published | Publication date | Source |
|---|---|---|---|
FY2024 | Balance sheet, P&L, persons | 9 Feb 2026 | North Data |
FY2023 | Balance sheet, P&L, persons | 3 Jan 2025 | North Data |
FY2022 | Balance sheet, P&L, persons | 1 Mar 2024 | North Data |
FY2021 | Balance sheet, P&L | 10 Jan 2023 | North Data |
FY2020 | Balance sheet, P&L | 14 Dec 2021 | North Data |
FY2019 | Balance sheet, P&L | 16 Dec 2020 | North Data |
FY2018 | Balance sheet only | 9 Dec 2019 | North Data |
FY2017 | Balance sheet only | 12 Dec 2018 | North Data |
FY2016 | Balance sheet only | 24 Nov 2017 | North Data |
FY2015 | Balance sheet; 5 holdings | 2 Dec 2016 | North Data |
FY2014 | Balance sheet; persons; 4 holdings | 7 Dec 2015 | North Data |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1 / 3 / 5 years) | Not applicable; unlisted |
Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B) | Not applicable; unlisted |
Analyst consensus | None; no coverage |
Buyback authorisations | None disclosed |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Share capital | EUR 100,000 (publication 20 Mar 2007) |
Capital Markets Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Share capital (EUR Mn) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Analyst Conclusions
Management guidance
None published.
Consensus expectations
None; no analyst coverage.
Bull case
-
Capsule IP becomes a licensable platform. Liquid-core capsule patents (DE/EP/WO/US/CA) and the proven nemaplus® Depot product could be licensed to larger nematode or biologicals firms, decoupling revenue from rearing scale.
-
New markets compound. Livestock fly control (VENDEX, 2026) and invasive-pest parasitoids (ParaDrosu, BiWaReg) open demand pools where Katz has first-mover know-how in Germany.
-
Automation closes the cost gap. AutoMiTec (EUR 287k, 2026) and InLight-type process gains could structurally lower rearing cost in predatory mites, the highest-volume macrobial category.
Bear case
-
Scale economics win. Koppert (EUR 435m revenue) and Biobest can underprice regional insectaries. Katz's reliance on 40+ bought-in products may mean partly reselling competitors' goods at thin margins.
-
R&D does not convert. A long sequence of grant projects since 2017 has produced one clearly named commercial capsule product. Several projects remain pre-commercial (BiWaReg to 2027).
-
Governance and succession. A founder-led, single-Vorstand, family-chaired structure, together with opaque financials and a EUR 0.1m capital base, limits growth capital and raises continuity risk.
Key catalysts and monitorables (next 12 months)
-
Publication of the FY2025 accounts (expected around Q1 2027, based on historical cadence). Key items: revenue (P&L disclosed), equity ratio and indebtedness.
-
Commercial follow-through from NemaKaps (completed March 2026), for example a field-vegetable capsule product.
-
Market traction and any extension of VENDEX and the Herdenschutz range.
-
AutoMiTec and DHYNAMite milestones.
-
Any change in Vorstand or Aufsichtsrat composition, or § 20 AktG shareholding notices signalling ownership change or a sale.
-
Status of the US liquid-core capsule application (17/789,913).
-
Sector M&A involving German insectaries.
Analyst verdict
Katz Biotech AG is not the "public company" the input list assumed. It is a family-controlled, unlisted German Aktiengesellschaft that has quietly assembled one of the more research-intensive profiles among Europe's second-tier beneficial-insect producers. Its corporate DNA combines an East German production lineage dating to 1980 with a West German founder-entrepreneur who started rearing beneficials in a basement in 1992. That heritage has produced a company with credible biological craft (about 15 species reared in-house), a full-range commercial offer and a durable relationship with Germany's public research system.
The investment-relevant question is whether that research engine can be monetised fast enough to offset structural scale disadvantages. Public evidence is mixed:
On the positive side: the encapsulation platform is real, patented across several jurisdictions and commercialised with e-nema. The company is also extending into livestock fly control and precision application, where incumbency is weak.
On the negative side: the global market is consolidating around players with hundreds of millions in revenue and private-equity backing. Katz still buys in most of its product range. Its R&D pipeline is long-dated and grant-dependent; there were no new federal awards in 2022–2023 before a rebound in 2024–2026.
Governance is the overriding uncertainty. A sole founder-Vorstand, a family supervisory-board chair, shareholder notifications in 2018 and a supervisory board change in 2025 all point to an ownership structure whose future intent is undisclosed.
Without access to the filed HGB financials, no view on valuation, profitability or leverage can responsibly be offered. Any counterparty, lender or acquirer should retrieve the FY2019–FY2024 accounts from the Unternehmensregister as a first step.
Overall assessment: a technically differentiated, strategically interesting niche asset, best viewed as a potential partnership, licensing or bolt-on acquisition target rather than a standalone scale player. Confidence in this view is low to moderate, constrained by the absence of verifiable financial data.
APPENDIX — SOURCE LIST
1: Katz Biotech AG – Home — https://katzbiotech.de
2: Katz Biotech AG – Impressum — https://katzbiotech.de/Menue/Impressum/
3: Katz Biotech AG – Über uns — https://katzbiotech.de/Ueber-Uns
4: Katz Biotech AG – Aktuelles — https://katzbiotech.de/Aktuelles
5: Katz Biotech AG – F&E — https://katzbiotech.de/F-E
6: Katz Biotech AG – Herdenschutz (B2B) — https://b2b.katzbiotech.de/Herdenschutz/
7: North Data – Katz Biotech AG, HRB 16819 P — https://www.northdata.de/Katz+Biotech+AG,+Baruth/Amtsgericht+Potsdam+HRB+16819+P
8: Patsnap Discovery – Katz Biotech — https://discovery.patsnap.com/company/katz-biotech
9: IPQwery – Katz Biotech AG patents — https://ipqwery.com/ipowner/en/owner/ip/5535736-katz-biotech-ag.html
10: Craft.co – Katz Biotech — https://craft.co/katz-biotech
11: 11880.com – Katz Biotech AG directory — https://www.11880.com/branchenbuch/baruth-mark/250321015B28945384/katz-biotech-ag.html
12: BioProtection Portal – e-nema / Katz Biotech capsules — https://bioprotectionportal.com/news/page/68
13: DPG Phytomedizin – Protocol PG 2007 — https://phytomedizin.org/fileadmin/documents/Ak/21_Kraueter/Doku/PROTOKOLL_PG2007.pdf
14: Orgprints – Peters, Katz, Elias (2008) — https://orgprints.org/view/creators/Katz=3AP=2E=3A=3A.html
15: Sächsische Gartenakademie – Suppliers of beneficials — https://www.gartenakademie.sachsen.de/download/Bezugsquellen_fuer_Nuetzlinge_Kleingarten.pdf
16: HAL Investments – Koppert — https://www.halinvestments.nl/koppert/
17: Doriane – Top 10 biologicals companies 2025 — https://www.doriane.com/blog/the-top-10-biologicals-companies-in-2025
18: AgFeed – Koppert in Brazil — https://agfeed.com.br/negocios/donos-da-koppert-lider-global-em-biologicos-invadem-a-america-a-partir-do-brasil
19: The AgriBiz – Koppert Brazil financials — https://www.theagribiz.com/?p=315458
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Education |
|---|---|---|---|---|
Dr. Peter Katz | Management Board (Vorstand), founder | Founder since 1992; Vorstand since at least the 2006 register entry | Founded PK-Nützlingszuchten (1992); presenter at DPG phytomedicine forums (2007); co-author on EPN research against codling moth (2008); named inventor on company patents | Doctorate (subject n/d) |
Jörg Rademacher | Head of R&D (Leiter F&E), ITC Berlin | — | Named co-inventor on liquid-core capsule patent | Diplom-Biologe |
Dr. Markus Hellmund | Research scientist (encapsulation / NemaKaps) | — | Co-inventor on liquid-core capsule patent; NemaKaps presenter (2026) | Diplom-Chemiker, Dr. rer. nat. |
Dr. Benjamin Walliser | Research scientist | — | — | M.Sc. Agrobiotechnology, Dr. rer. nat. |
Ghita Della Pasqua | Research scientist | — | — | M.Sc. Crop Sciences |
Sanjana Palika | Research scientist | — | — | M.Sc. Agricultural Entomology |
Christoph Hoff | Biological-technical assistant | — | — | BTA |
Vivien Hördel | Biological-technical assistant | — | — | BTA |
Martin Kamphusmann | Adviser (retail / end-sale beneficial use) | — | Webinar presenter 2026 | — |
Ralf Weber | Livestock (Herdenschutz) adviser | c. 2025– | 25+ years in dairy production; member of an examination board for agricultural trainees | Agricultural engineer (Agraringenieur) |
Andrea Häussler | Named co-inventor (liquid-core capsules) | — | — | — |
Board of Directors
| Name | Role | Independence | Source |
|---|---|---|---|
Kirsten Katz | Chair | Not independent in the conventional sense; family name indicates a family relationship with the CEO, but the precise relationship is not disclosed | Impressum |
Other members | Members (German AG law requires a minimum of three) | — | Lists filed 2016 and May/June 2025 (contents not accessible) |
Board & Management Changes
| Date | Change | Context | Source |
|---|---|---|---|
30 May / 13 Jun 2025 | Updated list of supervisory board members filed | Indicates change in Aufsichtsrat composition; names n/d | North Data |
c. 2025 | Appointment of dedicated livestock adviser (Ralf Weber) | Supports the new Herdenschutz line | Herdenschutz page |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Holders notified under § 20 AktG (2018) | Holdings above statutory thresholds (25% / majority) notified; names and stakes n/d | North Data (three announcements Nov–Dec 2018) |
Institutional ownership (top 10) | Not applicable / not publicly disclosed | — |
Competitive Landscape
Key Competitors
| Competitor | HQ | Type | Overlap with Katz Biotech | Scale indicator | Source |
|---|---|---|---|---|---|
Koppert | Berkel en Rodenrijs, NL | Family-owned; HAL Investments 27.3% | Full macrobial range, greenhouse IPM, Germany and Europe | Revenue EUR 435m; EBITDA EUR 34m; 2,683 employees (HAL) | HAL Investments |
Biobest (BioFirst Group) | Westerlo, BE | Private | Macrobials, pollination, biologicals | Targets USD 2bn biologicals revenue by 2035; acquired Biotrop 2023 | Doriane; AgFeed |
Syngenta Biologicals | Basel, CH | Corporate division | Biologicals (mainly microbials and biostimulants) | Biologicals revenue about USD 400m (as of Mar 2024) | Doriane |
UPL (NPP) | IN / global | Corporate division | Natural plant protection | NPP revenue USD 365m (2024) | Doriane |
FMC Biologicals | US | Corporate division | Biologicals | USD 240m (2024), +33% | Doriane |
e-nema GmbH | Schwentinental, DE | Private | Entomopathogenic nematodes (also a partner) | — | Sachsen Gartenakademie list |
Sautter & Stepper GmbH | Ammerbuch, DE | Private | Beneficials for gardens and professionals | — | Sachsen Gartenakademie list |
Re-natur GmbH | Stolpe, DE | Private | Beneficials and biological plant protection | — | Sachsen Gartenakademie list |
W. Neudorff GmbH KG | Emmerthal, DE | Private | Home and garden biologicals including beneficials | — | Sachsen Gartenakademie list |
Andermatt Group / Bioline AgroSciences | CH / UK | Private | Macrobials and biologicals | — | Industry knowledge; figures n/d |
Peer Comparison FY2025
| Metric | Koppert | Syngenta Biologicals |
|---|---|---|
Revenue | EUR 435m | about USD 400m |
EBITDA margin | about 7.8% (EUR 34m / EUR 435m) | — |
Employees | 2,683 | n/a (division) |
Recent Developments
Not identified in the period: * guidance revisions, litigation, regulatory actions, restructurings, layoffs, or major contract wins.



